Learning Objectives
- Gain an understanding of the landscape of diabetes and cardiovascular disease
- Discuss the rationale for the FDA guidance around cardiovascular safety of antihyperglycemic agents
- Evaluate the data on the recent large trials of antihyperglycemic agents on cardiovascular safety and efficacy
- Evaluate how the EMPA-REG trial will impact clinical practice
This program has been accredited by the College of Family Physicians of Canada for up to 1 Mainpro-M1 credits
Chair
Peter J Lin
MD, CCFP
Director, Primary Care Initiative
Canadian Heart Research Centre
Medical Director, LinCorp Medical Inc.
Faculty
Subodh Verma
MD, PhD, FRCSC, FAHA
Division of Cardiac Surgery, St. Michael’s Hospital
Professor Surgery and Pharmacology & Toxicology, University of Toronto
Lawrence A Leiter
MD, FRCPC, FACP, FACE, FAHA
Division of Endochrinology & Metabolism, St. Michael’s Hospital
Professor of Medicine & Nutritional Sciences, University of Toronto
Bernard Zinman
CM, MD, FRCP, FACP
Director, Diabetes Centre, Mount Sinai Hospital
Professor of Medicine, University of Toronto
Alice Y Y Cheng
MD, FRCPC
Division of Endocrinology, Credit Valley Hospital and St. Michael’s Hospital
Associate Professor of Medicine, University of Toronto
This program is supported by an educational grant from:
Video Information
- Session ID:177956
- Credit:1 Mainpro-M1 credits
- Post Date:April 28, 2016
- Expiry Date:February 5, 2017
